One in 8 women in the EU will develop breast cancer before the age of 85. This disease is associated with a great economic cost. In fact, in 2010 it was estimated at more than €15 billion in Europe. About 46% of the breast cancer cost is spent on treatments and drugs1 that are selected by general guidelines and may not be efficient for a specific patient.
1 in 8
women will developer it
>€ 15 billion cost
Drugs selected by general
Led by IBM, this pilot supports precision medicine to improve accuracy in diagnosis and propose treatments that are more targeted, less toxic and therefore better tolerated.
1 Source: Capri S., Russo A.: Cost of breast cancer based on real-world data: a cancer registry study in Italy, BMC health Services Research, 17(1):84, 2017.